Peptide Association
Daily Peptide News

Latest Peptide News & Research

Breaking research, regulatory updates, and industry developments in the world of peptide science. Updated daily.

Last updated: April 30, 2026 at 6:00 AM

RegulatoryCritical

Opinion: STAT+: Did Kennedy just stack the deck on FDA oversight of peptides?

A significant shift in FDA oversight of peptides may be underway following signals from Health and Human Services Secretary Robert F. Kennedy Jr. regarding upcoming policy changes affecting the regulatory landscape for peptide therapies. The move has drawn considerable attention from compounding pharmacies, peptide manufacturers, and clinicians who rely on access to peptide-based treatments. Analysts are closely watching how any restructuring of FDA authority could reshape the approval pathway and availability of both compounded and commercially developed peptides.

STAT NewsApril 29, 2026
5 min read
Clinical TrialsHigh

Boehringer, Zealand's obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound

Boehringer Ingelheim and Zealand Pharma reported that their investigational obesity injection achieved nearly 17% weight loss over approximately 18 months, positioning it as a competitive alternative to semaglutide-based therapies. The results place the candidate on par with Novo Nordisk's Wegovy but below the efficacy benchmarks set by Lilly's dual GIP/GLP-1 agonist Zepbound. The data adds further momentum to the expanding landscape of injectable peptide-based obesity treatments vying for market share.

SemaglutideTirzepatideGLP-1GIP
Endpoints NewsApril 28, 2026
4 min read
ResearchHigh

What's the true risk for eating disorders with GLP-1s?

Emerging safety discussions around GLP-1 receptor agonists such as semaglutide continue to draw clinical scrutiny, with researchers and clinicians examining the potential association between these widely prescribed medications and eating disorder risk. Understanding the behavioral and psychological side effects of GLP-1 therapies is increasingly important as patient populations expand. This analysis contributes to the ongoing effort to characterize the full safety profile of GLP-1 based treatments in real-world settings.

GLP-1Semaglutide
STAT NewsApril 27, 2026
4 min read
ResearchCritical

GLP-1 Drugs Tirzepatide and Semaglutide Provide Protection for Heart Health

A major new real-world study from Mass General Brigham found that both tirzepatide and semaglutide significantly reduced the risk of heart attack, stroke, and death from any cause. The STEER study found that semaglutide 2.4 mg demonstrated a 57% greater reduction in major cardiovascular adverse events, cardiovascular-related death, or all-cause death compared with tirzepatide. The findings provide critical head-to-head data comparing the two leading GLP-1 receptor agonists on cardiovascular outcomes in real clinical practice.

SemaglutideTirzepatideGLP-1
Mass General BrighamMarch 29, 2026
5 min read
ResearchHigh

GLP-1 Agonists Could Be a Global Game-Changer but Need to Be Accessible and Affordable

A comprehensive analysis presented at CROI 2026 shows that popular GLP-1 weight-loss medications generally work well for people living with HIV, and may improve liver, gut, and cardiovascular health while reducing smoking alongside their well-known benefits for obesity and diabetes. The findings expand the therapeutic potential of GLP-1 drugs into infectious disease management. However, researchers and advocates emphasize that cost and access barriers must be addressed for these medications to realize their global public health potential.

SemaglutideTirzepatideGLP-1
aidsmapMarch 28, 2026
5 min read
ResearchHigh

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook

NeurologyLive reviews the growing body of evidence for repurposing GLP-1 receptor agonists in neurological conditions including Alzheimer's disease, Parkinson's disease, and sleep disorders. The analysis covers the mechanistic basis for neuroprotection through anti-inflammatory, anti-amyloid, and metabolic pathways, and surveys the expanding clinical trial landscape. Researchers describe GLP-1 receptor agonists as one of the most tractable drug repurposing opportunities for neurodegeneration, though results from ongoing trials remain mixed but promising.

SemaglutideLiraglutideGLP-1
NeurologyLiveMarch 27, 2026
6 min read
RegulatoryHigh

BPC-157 Is Coming Back: What RFK Jr.'s FDA Peptide Announcement Means for Patients

AgeMD breaks down what the expected FDA reclassification of BPC-157 from Category 2 back to Category 1 means for patients and providers. The article clarifies that reclassification does not equal FDA approval; these peptides will remain off-label therapeutics requiring physician supervision, proper dosing, and ongoing monitoring. With the formal updated list still pending from the FDA, the piece advises patients to work only with licensed compounding pharmacies and qualified medical providers rather than turning to gray-market sources.

BPC-157TB-500IpamorelinMOTS-c
AgeMDMarch 27, 2026
4 min read
RegulatoryHigh

The Wellness World Is Eager for RFK Jr.'s Promised Move on Peptides

NPR reports that the wellness industry is watching closely as Health Secretary Robert F. Kennedy Jr.'s promised FDA peptide reclassification remains pending weeks after his initial announcement. The universe of peptide providers spans high-end clinics, large wellness chains, med spas, and websites advertising research-grade peptides not intended for human use. While supporters argue the change is necessary to bring consumers to ethical suppliers, critics note these compounds have largely not been tested for safety or efficacy in human trials, with evidence mostly coming from animal studies and cell cultures.

BPC-157IpamorelinMOTS-c
NPRMarch 31, 2026
5 min read
Clinical TrialsHigh

Orforglipron Maintains Weight Loss in Patients Switching from Semaglutide or Tirzepatide

Results from the ATTAIN-MAINTAIN trial show that orforglipron, a novel oral GLP-1 receptor agonist, demonstrated superior weight maintenance compared to placebo in patients transitioning from injectable semaglutide or tirzepatide therapy. The findings suggest patients can successfully switch from injections to an oral formulation without losing their weight loss progress, a significant development for long-term treatment adherence. Orforglipron could represent a major shift in the GLP-1 landscape by offering a convenient pill-based alternative to weekly injections.

SemaglutideTirzepatideOrforglipronGLP-1
HCPLiveMarch 30, 2026
4 min read
RegulatoryCritical

FDA Weighs Peptide Compounding Rules as Industry Awaits Formal Reclassification

STAT News reports that the FDA is actively reviewing its policies on peptide compounding, with the agency expected to issue updated guidance following HHS Secretary RFK Jr.'s February announcement that approximately 14 of 19 restricted peptides would be moved back to Category 1. The pharmaceutical industry and compounding pharmacies are closely watching for the formal reclassification, which would restore legal access to widely used compounds including BPC-157 and ipamorelin through licensed compounding pharmacies with a physician's prescription. The delay between the announcement and formal action has created uncertainty across the supply chain.

BPC-157IpamorelinMOTS-c
STAT NewsApril 1, 2026
5 min read
ResearchMedium

Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity

Using the All of Us research program database, this nested case-control study found a potentially reduced risk of substance use disorders among patients with type 2 diabetes or obesity who were prescribed GLP-1 receptor agonists. The findings align with emerging preclinical and clinical evidence suggesting GLP-1 agents may modulate dopaminergic reward pathways involved in addictive behavior. The research opens a novel translational direction for GLP-1 therapies beyond metabolic disease management.

SemaglutideTirzepatideGLP-1
Front Psychiatry2026
5 min read
ResearchHigh

Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis

A systematic review and meta-analysis published in Brain and Behavior evaluated GLP-1 receptor agonists as a potential therapeutic strategy for Parkinson's disease, synthesizing data from available clinical trials. The analysis found promising signals for neuroprotective and symptom-modifying effects, building on earlier Phase 2 trial results that showed cognitive and motor benefits in this population. The authors called for larger, adequately powered trials to validate efficacy and determine optimal dosing and treatment duration.

SemaglutideLiraglutideGLP-1
Brain BehavApril 2026
6 min read
ResearchHigh

Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders

Published in Nature Aging, this authoritative review by Sabbagh, Cummings, and Ballard examines the growing body of evidence for repurposing GLP-1 receptor agonists in neurodegenerative diseases including Alzheimer's and Parkinson's. The authors outline the mechanistic basis for neuroprotection—including anti-inflammatory, anti-amyloid, and metabolic pathways—and survey the clinical trial landscape currently testing these hypotheses. The paper argues that GLP-1 receptor agonists represent one of the most tractable drug repurposing opportunities for neurodegeneration.

SemaglutideLiraglutideGLP-1
Nature AgingJanuary 2026
7 min read
ResearchHigh

Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity

This analysis published in ESC Heart Failure evaluated the role of GLP-1 receptor agonists in preventing heart failure hospitalizations and related events in patients with type 2 diabetes and/or obesity. The study adds to accumulating evidence that GLP-1 drugs offer cardiovascular protection that extends beyond glycemic and weight management. Researchers noted variability in effect size across individual agents, suggesting drug-specific rather than class-wide effects may be driving outcomes.

SemaglutideTirzepatideLiraglutideGLP-1
ESC Heart FailMarch 25, 2026
5 min read
LongevityMedium

Ginseng Oligopeptides Promote Longevity and Enhance Stress Resistance in Caenorhabditis elegans via the DAF-16/FOXO Pathway

Researchers demonstrated that ginseng-derived oligopeptides significantly extended lifespan and improved stress resistance in the well-validated model organism C. elegans by activating the DAF-16/FOXO signaling pathway, a conserved longevity cascade also relevant in mammals. The study adds to a growing body of research identifying plant-derived peptides as candidate geroprotective agents with potential for future longevity applications. While findings are preclinical, they provide a mechanistic foundation supporting further investigation of ginseng oligopeptides in aging research.

Ginseng Oligopeptides
AntioxidantsNovember 21, 2025
5 min read
ResearchMedium

Research on epicardial adipose tissue as a metabolic therapeutic target in AF: focus on GLP-1 receptor agonists

A Frontiers in Cardiovascular Medicine review explores epicardial adipose tissue (EAT) as a driver of atrial fibrillation and examines whether GLP-1 receptor agonists can reduce arrhythmia risk by targeting this metabolically active fat depot. The authors synthesize preclinical and clinical evidence suggesting GLP-1 agonists may reduce EAT volume and associated inflammatory signaling linked to AF onset and recurrence. The review identifies GLP-1 pathway modulation as a promising adjunct strategy in the management of metabolic-driven atrial fibrillation.

GLP-1
Frontiers in Cardiovascular MedicineMarch 23, 2026
6 min read
ResearchMedium

Association of GLP-1 Receptor Agonist Use with Hypersomnolence: A Real-world Cohort Analysis

A real-world cohort study in the Journal of Diabetes and Metabolic Disorders investigated whether GLP-1 receptor agonist use is associated with increased rates of hypersomnolence, or excessive daytime sleepiness. Researchers identified a signal in the data warranting further investigation, as the mechanism may relate to central nervous system effects or changes in sleep architecture secondary to weight loss and metabolic shifts. The findings highlight the importance of monitoring neurological and sleep-related side effects as GLP-1 prescribing continues to expand.

GLP-1
Journal of Diabetes and Metabolic DisordersJune 2026
4 min read
ResearchMedium

Outcomes of primary rotator cuff repair in non-diabetic patients using glucagon-like peptide-1 (GLP-1) receptor agonists: A propensity-matched analysis

Researchers published a propensity-matched analysis in Shoulder & Elbow assessing whether GLP-1 receptor agonist use affects healing outcomes following primary rotator cuff repair in non-diabetic patients. The study addresses growing clinical questions about whether GLP-1 drugs, increasingly used for obesity in non-diabetic populations, influence tendon repair biology or surgical recovery. Results provide early real-world evidence on a clinically relevant but previously unexplored question in orthopedic surgery.

GLP-1
Shoulder ElbowMarch 20, 2026
5 min read
ResearchMedium

Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD

A secondary analysis of a randomized controlled trial published in Clinical Obesity examined whether liraglutide treatment improved obstructive sleep apnea severity and quality-of-life measures in obese patients who also had COPD. The exploratory findings suggest modest improvements in sleep-related outcomes alongside weight loss, though the study was not powered to confirm these effects. Authors recommend dedicated trials to evaluate GLP-1 receptor agonists as adjunct therapy for respiratory comorbidities of obesity.

Liraglutide
Clinical ObesityApril 2026
5 min read
ResearchMedium

GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research

A narrative review in Sexual Medicine Reviews surveys the emerging body of research on how GLP-1 receptor agonists may influence sexual function in both men and women, noting improvements in libido and erectile function potentially tied to weight loss and reduced inflammation. The authors caution that data remains limited and largely observational, calling for dedicated clinical trials to disentangle direct drug effects from weight-loss-mediated changes. The review identifies sexual health as a meaningful but understudied domain in GLP-1 therapy outcomes.

SemaglutideTirzepatide
Sex Med RevJanuary 5, 2026
5 min read
Clinical TrialsHigh

Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy

A study in the Journal of Clinical Endocrinology & Metabolism evaluates tirzepatide, the dual GIP/GLP-1 receptor agonist, as a treatment option for patients with partial lipodystrophy, a rare disorder of adipose tissue distribution often associated with metabolic complications. Researchers found that tirzepatide improved metabolic parameters in this underserved patient population, suggesting a potential new therapeutic application beyond typical obesity and type 2 diabetes indications. The findings highlight the drug's versatility and could broaden its clinical use.

Tirzepatide
J Clin Endocrinol MetabMarch 20, 2026
5 min read
ResearchHigh

Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations

A review published in the Journal of the Chinese Medical Association examines emerging clinical evidence linking GLP-1 receptor agonist use to a range of ocular complications, including nonarteritic anterior ischemic optic neuropathy. The authors analyze proposed biological mechanisms by which rapid glycemic changes induced by these drugs may stress optic nerve vasculature. Clinicians are advised to monitor high-risk patients and weigh ocular risks when prescribing GLP-1 therapies.

SemaglutideTirzepatide
J Chin Med AssocMarch 17, 2026
6 min read
ResearchHigh

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications

A review in Current Cardiology Reports assesses the evidence for oral GLP-1 receptor agonists, such as orforglipron and oral semaglutide, in reducing cardiorenal complications including heart failure and chronic kidney disease progression. The authors evaluate how oral formulations compare to injectable counterparts in terms of bioavailability, patient adherence, and clinical outcomes. The findings support expanding oral GLP-1 options as a strategy to improve long-term cardiovascular and renal health in patients with diabetes and obesity.

Semaglutide
Curr Cardiol RepMarch 23, 2026
6 min read
IndustryMedium

TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trends

A study published in the Journal of the American Pharmacists Association analyzes how TikTok and broader social media platforms have dramatically amplified public interest in and demand for GLP-1 receptor agonists for weight loss. Researchers examined the content, reach, and accuracy of GLP-1-related posts, finding significant misinformation alongside genuine patient testimonials. The authors call for pharmacists and clinicians to play a more active role in countering misleading social media health claims about these medications.

SemaglutideTirzepatide
J Am Pharm AssocMarch 20, 2026
4 min read
Clinical TrialsMedium

Continuous Versus Bolus Terlipressin for Acute Oesophageal Variceal Bleeding and Hepatorenal Syndrome in Cirrhosis: Meta-Analysis

A meta-analysis published in Liver International compared continuous infusion versus bolus dosing of terlipressin, a synthetic vasopressin analogue peptide, in cirrhosis patients experiencing acute oesophageal variceal bleeding or hepatorenal syndrome. The study assessed differences in efficacy and adverse event profiles between the two administration strategies. Findings provide clinicians with evidence-based guidance on optimizing terlipressin dosing in acute liver disease emergencies.

Terlipressin
Liver IntApril 2026
4 min read